STAMFORD, Conn., Sept. 24 /PRNewswire/ -- Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that Ingrid Blair, global business manager for 3M's Infection Prevention Division, has joined Zargis' Board of Directors. 3M gained the right to an appointment on Zargis' board as part of the previously announced exclusive global marketing and distribution alliance between Zargis and 3M.
"Ingrid brings a wealth of knowledge to Zargis, having managed global expansions of high-growth healthcare businesses," said John Kallassy, Zargis' CEO. "We are excited to have Ingrid as a board member and look forward to her guidance as we roll-out Zargis Cardioscan(TM) worldwide."
"Zargis has done an outstanding job in creating revolutionary software products that seamlessly interact with the new 3M Littmann Model 3200 Stethoscope and I look forward to participating with Zargis on behalf of 3M," said Ingrid Blair. "Widespread adoption of Zargis Cardioscan, when paired with the 3200 stethoscope, assists practitioners as healthcare efficiency grows in importance."
About 3M Health Care
3M Health Care, one of 3M's six major business segments, provides world-class innovative products and services to help health care professionals improve the practice, delivery and outcome of patient care in medical, oral care, drug delivery and health information markets.
For more information, visit www.3M.com.
About Zargis Medical Corp.
Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. (Nasdaq: SPDE) co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com, or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Zargis Medical Corp.
